↓ Skip to main content

The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma

Overview of attention for article published in Molecular Oncology, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
2 news outlets
twitter
4 X users

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
63 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma
Published in
Molecular Oncology, November 2014
DOI 10.1016/j.molonc.2014.11.002
Pubmed ID
Authors

Rocío Montes de Oca, Zachary A. Gurard-Levin, Frédérique Berger, Haniya Rehman, Elise Martel, Armelle Corpet, Leanne de Koning, Isabelle Vassias, Laurence O.W. Wilson, Didier Meseure, Fabien Reyal, Alexia Savignoni, Bernard Asselain, Xavier Sastre-Garau, Geneviève Almouzni

Abstract

Breast cancer is a heterogeneous disease with different molecular subtypes that have varying responses to therapy. An ongoing challenge in breast cancer research is to distinguish high-risk patients from good prognosis patients. This is particularly difficult in the low-grade, ER-positive luminal A tumors, where robust diagnostic tools to aid clinical treatment decisions are lacking. Recent data implicating chromatin regulators in cancer initiation and progression offers a promising avenue to develop new tools to help guide clinical decisions.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 62 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 21%
Student > Ph. D. Student 11 17%
Student > Master 8 13%
Student > Bachelor 7 11%
Student > Doctoral Student 4 6%
Other 7 11%
Unknown 13 21%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 18 29%
Agricultural and Biological Sciences 11 17%
Medicine and Dentistry 9 14%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Nursing and Health Professions 2 3%
Other 5 8%
Unknown 15 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2023.
All research outputs
#1,765,703
of 25,109,675 outputs
Outputs from Molecular Oncology
#81
of 1,689 outputs
Outputs of similar age
#23,826
of 374,880 outputs
Outputs of similar age from Molecular Oncology
#2
of 24 outputs
Altmetric has tracked 25,109,675 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,689 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 374,880 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.